This article was originally published in The Gray Sheet
Acquisition of development stage CardioGene Therapeutics gives the Natick, Massachusetts firm a foothold in the gene therapy market for cardiovascular diseases such as angiogenesis, restenosis and congestive heart failure. Boston Scientific the purchases all outstanding stock in the Princeton, New Jersey firm, which holds patent positions covering the "use of device technology for delivery of genetic material to sites within the vasculature and the myocardium"
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.